Fideuram Asset Management Ireland dac Makes New $572,000 Investment in Edwards Lifesciences Corporation $EW

Fideuram Asset Management Ireland dac bought a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 6,713 shares of the medical research company’s stock, valued at approximately $572,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in EW. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Edwards Lifesciences by 278.3% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock worth $434,318,000 after acquiring an additional 4,108,270 shares during the last quarter. Viking Global Investors LP purchased a new position in shares of Edwards Lifesciences during the third quarter worth $238,688,000. AQR Capital Management LLC boosted its position in shares of Edwards Lifesciences by 114.5% during the third quarter. AQR Capital Management LLC now owns 2,081,346 shares of the medical research company’s stock worth $161,055,000 after buying an additional 1,111,139 shares during the period. Northwestern Mutual Wealth Management Co. boosted its position in shares of Edwards Lifesciences by 1,952.7% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,149,700 shares of the medical research company’s stock worth $98,012,000 after buying an additional 1,093,692 shares during the period. Finally, Schroder Investment Management Group boosted its position in shares of Edwards Lifesciences by 1,657.4% during the third quarter. Schroder Investment Management Group now owns 1,133,475 shares of the medical research company’s stock worth $88,150,000 after buying an additional 1,068,979 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently commented on EW shares. Barclays restated an “overweight” rating and set a $110.00 price target (up from $104.00) on shares of Edwards Lifesciences in a research report on Monday, April 27th. Piper Sandler restated an “overweight” rating and set a $100.00 price target (up from $98.00) on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. Truist Financial set a $90.00 price target on Edwards Lifesciences and gave the stock a “hold” rating in a research report on Friday, April 24th. Mizuho set a $95.00 price target on Edwards Lifesciences and gave the stock an “outperform” rating in a research report on Monday, April 13th. Finally, UBS Group restated a “neutral” rating and set a $94.00 price target on shares of Edwards Lifesciences in a research report on Wednesday, February 4th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $95.65.

Edwards Lifesciences Trading Up 0.5%

NYSE:EW opened at $86.41 on Friday. The firm has a market cap of $49.76 billion, a PE ratio of 45.96, a price-to-earnings-growth ratio of 2.17 and a beta of 0.87. The stock has a fifty day moving average price of $81.73 and a 200 day moving average price of $83.01. Edwards Lifesciences Corporation has a 12-month low of $72.30 and a 12-month high of $88.28. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.05. The firm had revenue of $1.65 billion during the quarter, compared to analyst estimates of $1.60 billion. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.Edwards Lifesciences’s revenue was up 16.7% compared to the same quarter last year. During the same period last year, the business posted $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Sell-side analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Insider Activity at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 23,145 shares of Edwards Lifesciences stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total value of $2,000,190.90. Following the completion of the transaction, the vice president directly owned 98,611 shares in the company, valued at approximately $8,521,962.62. This trade represents a 19.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Daniel J. Lippis sold 1,019 shares of Edwards Lifesciences stock in a transaction on Friday, May 1st. The shares were sold at an average price of $83.01, for a total value of $84,587.19. Following the completion of the transaction, the vice president owned 33,934 shares of the company’s stock, valued at approximately $2,816,861.34. This trade represents a 2.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 106,397 shares of company stock worth $8,848,664. Company insiders own 0.31% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.